Dec 19 (Reuters) - Anglo-Swedish drugmaker AstraZeneca Plc said on Friday it signed an agreement to develop and commercialise U.S.-based MAP Pharmaceuticals' pediatric asthma drug. Sign up here ...

Achilles Therapeutics transferred TRACERx data and samples to AstraZeneca, finalizing a strategic review and receiving $12M.

AstraZeneca has terminated its collaboration with the USA’s MAP Pharmaceuticals which involved the development of a potential asthma treatment for children some four months after the drug failed in a ...

In a presentation to investors, AstraZeneca laid out its game plan for building sales on existing therapies like Crestor while beefing up its pipeline of experimental drugs. But few analysts ...

BANGALORE (Reuters) - MAP Pharmaceuticals said it plans to suspend development of its experimental paediatric asthma drug, after its licensing partner AstraZeneca terminated a collaboration on the ...

The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004, was well tolerated by patients in an early-stage clinical trial.

AstraZeneca has suffered another clinical disappointment following the news that a late-stage trial by partner MAP Pharmaceuticals looking at a potential asthma treatment for children has fallen by ...

In the meantime, AstraZeneca faces the loss of patent protection on its cholesterol-fighting blockbuster Crestor later this year--a big sales blow, Soriot said during last quarter's earnings call ...

- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON ...

Here’s a map showing select pharmacies across Toronto, Kingston, and Windsor regions that are offering AstraZeneca shots for people aged 60 to 64.

“Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts.

In its first deal with a major drugmaker, MAP Pharmaceuticals Inc. has joined with London-based AstraZeneca to develop and commercialize a nebulized form of budesonide, a potential treatment for ...